Jonathan Silverstein - Net Worth and Insider Trading

Jonathan Silverstein Net Worth

The estimated net worth of Jonathan Silverstein is at least $638 Million dollars as of 2024-11-13. Jonathan Silverstein is the Director, 10% Owner of Relypsa Inc and owns about 9,941,551 shares of Relypsa Inc (RLYP) stock worth over $318 Million. Jonathan Silverstein is the Director, 10% Owner of Audentes Therapeutics Inc and owns about 4,801,638 shares of Audentes Therapeutics Inc (BOLD) stock worth over $288 Million. Jonathan Silverstein is also the Director of Intercept Pharmaceuticals Inc and owns about 1,120,324 shares of Intercept Pharmaceuticals Inc (ICPT) stock worth over $21 Million. Besides these, Jonathan Silverstein also holds Arcutis Biotherapeutics Inc (ARQT) , resTORbio Inc (TORC) , Glaukos Corp (GKOS) . Details can be seen in Jonathan Silverstein's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jonathan Silverstein has not made any transactions after 2020-10-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jonathan Silverstein

Jonathan Silverstein Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jonathan Silverstein owns 12 companies in total, including Arcutis Biotherapeutics Inc (ARQT) , Avedro Inc (AVDR) , and Glaukos Corp (GKOS) among others .

Click here to see the complete history of Jonathan Silverstein’s form 4 insider trades.

Insider Ownership Summary of Jonathan Silverstein

Ticker	Comapny	Transaction Date	Type of Owner
ARQT	Arcutis Biotherapeutics Inc	2020-10-02	director & 10 percent owner
AVDR	Avedro Inc	2019-11-21	director & 10 percent owner
GKOS	Glaukos Corp	2018-03-06	director
		2017-11-16	director
		2017-10-04	director & 10 percent owner
		2016-09-21	director & 10 percent owner
		2016-08-24	director & 10 percent owner
		2015-03-26	director
		2013-11-20	director & 10 percent owner
		2010-05-27	director & 10 percent owner
		2007-05-14	director
		2018-01-25	director & 10 percent owner

Jonathan Silverstein Latest Holdings Summary

Jonathan Silverstein currently owns a total of 6 stocks. Among these stocks, Jonathan Silverstein owns 9,941,551 shares of Relypsa Inc (RLYP) as of November 20, 2013, with a value of $318 Million and a weighting of 49.84%. Jonathan Silverstein owns 4,801,638 shares of Audentes Therapeutics Inc (BOLD) as of July 25, 2016, with a value of $288 Million and a weighting of 45.13%. Jonathan Silverstein also owns 1,120,324 shares of Intercept Pharmaceuticals Inc (ICPT) as of March 26, 2015, with a value of $21 Million and a weighting of 3.34%. The other 3 stocks Arcutis Biotherapeutics Inc (ARQT) , resTORbio Inc (TORC) , Glaukos Corp (GKOS) have a combined weighting of 1.7% among all his current holdings.

Latest Holdings of Jonathan Silverstein

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
RLYP	Relypsa Inc	2013-11-20	9,941,551	31.99	318,030,216
BOLD	Audentes Therapeutics Inc	2016-07-25	4,801,638	59.97	287,954,231
ICPT	Intercept Pharmaceuticals Inc	2015-03-26	1,120,324	19.00	21,286,156
ARQT	Arcutis Biotherapeutics Inc	2020-10-02	902,286	10.25	9,248,432
TORC	resTORbio Inc	2018-01-30	690,055	2.28	1,573,325
GKOS	Glaukos Corp	2018-03-06	0	143.63	0

Holding Weightings of Jonathan Silverstein

Jonathan Silverstein Form 4 Trading Tracker

According to the SEC Form 4 filings, Jonathan Silverstein has made a total of 0 transactions in Relypsa Inc (RLYP) over the past 5 years. The most-recent trade in Relypsa Inc is the acquisition of 712,192 shares on November 20, 2013, which cost Jonathan Silverstein around $8 Million.

According to the SEC Form 4 filings, Jonathan Silverstein has made a total of 0 transactions in Audentes Therapeutics Inc (BOLD) over the past 5 years. The most-recent trade in Audentes Therapeutics Inc is the acquisition of 33,334 shares on July 25, 2016, which cost Jonathan Silverstein around $500,010.

According to the SEC Form 4 filings, Jonathan Silverstein has made a total of 0 transactions in Intercept Pharmaceuticals Inc (ICPT) over the past 5 years. The most-recent trade in Intercept Pharmaceuticals Inc is the sale of 157,200 shares on March 26, 2015, which brought Jonathan Silverstein around $45 Million.

More details on Jonathan Silverstein's insider transactions can be found in the Insider Trading History of Jonathan Silverstein table.

Insider Trading History of Jonathan Silverstein

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jonathan Silverstein Trading Performance

GuruFocus tracks the stock performance after each of Jonathan Silverstein's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jonathan Silverstein is 49.37%. GuruFocus also compares Jonathan Silverstein's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jonathan Silverstein within 3 months outperforms 5 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jonathan Silverstein's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jonathan Silverstein

Average Return

Average return per transaction

Outperforming Transactions

5 out of 6 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	20.13
Relative Return to S&P 500(%)	23.07

Jonathan Silverstein Ownership Network

Ownership Network List of Jonathan Silverstein

No Data

Ownership Network Relation of Jonathan Silverstein

Jonathan Silverstein Owned Company Details

What does Arcutis Biotherapeutics Inc do?

Who are the key executives at Arcutis Biotherapeutics Inc?

Jonathan Silverstein is the director & 10 percent owner of Arcutis Biotherapeutics Inc. Other key executives at Arcutis Biotherapeutics Inc include director & President and CEO Todd Franklin Watanabe , See Remarks Patrick Burnett , and SVP and General Counsel Masaru Matsuda .

Arcutis Biotherapeutics Inc (ARQT) Insider Trades Summary

Over the past 18 months, Jonathan Silverstein made no insider transaction in Arcutis Biotherapeutics Inc (ARQT). Other recent insider transactions involving Arcutis Biotherapeutics Inc (ARQT) include a net sale of 119,269 shares made by Patrick Burnett , a net sale of 24,466 shares made by Masaru Matsuda , and a net sale of 60,000 shares made by Howard G. Welgus .

In summary, during the past 3 months, insiders sold 81,406 shares of Arcutis Biotherapeutics Inc (ARQT) in total and bought 0 shares, with a net sale of 81,406 shares. During the past 18 months, 294,384 shares of Arcutis Biotherapeutics Inc (ARQT) were sold and 102,515 shares were bought by its insiders, resulting in a net sale of 191,869 shares.

Arcutis Biotherapeutics Inc (ARQT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arcutis Biotherapeutics Inc Insider Transactions

No Available Data

What does Avedro Inc do?

Who are the key executives at Avedro Inc?

Jonathan Silverstein is the director & 10 percent owner of Avedro Inc. Other key executives at Avedro Inc include 10 percent owner Arnold L Oronsky , 10 percent owner Gilbert H Kliman , and General Counsel and Sec. Paul S Bavier .

Avedro Inc (AVDR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Avedro Inc (AVDR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Avedro Inc (AVDR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Avedro Inc (AVDR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avedro Inc Insider Transactions

No Available Data

What does Glaukos Corp do?

Who are the key executives at Glaukos Corp?

Jonathan Silverstein is the director of Glaukos Corp. Other key executives at Glaukos Corp include CFO & SVP Corporate Development Joseph E Gilliam , SVP & Chief Financial Officer Alex R. Thurman , and director & 10 percent owner & Chief Executive Officer Thomas William Burns .

Glaukos Corp (GKOS) Insider Trades Summary

Over the past 18 months, Jonathan Silverstein made no insider transaction in Glaukos Corp (GKOS). Other recent insider transactions involving Glaukos Corp (GKOS) include a net sale of 311,429 shares made by Joseph E Gilliam , a net sale of 520,000 shares made by Thomas William Burns , and a net sale of 6,762 shares made by Alex R. Thurman .

In summary, during the past 3 months, insiders sold 16,525 shares of Glaukos Corp (GKOS) in total and bought 0 shares, with a net sale of 16,525 shares. During the past 18 months, 942,098 shares of Glaukos Corp (GKOS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 942,098 shares.

Glaukos Corp (GKOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Glaukos Corp Insider Transactions

No Available Data

What does scPharmaceuticals Inc do?

Who are the key executives at scPharmaceuticals Inc?

Jonathan Silverstein is the director of scPharmaceuticals Inc. Other key executives at scPharmaceuticals Inc include 10 percent owner Orbimed Advisors Llc , 10 percent owner 5am Partners Iv, Llc , and director & President and CEO John H Tucker .

scPharmaceuticals Inc (SCPH) Insider Trades Summary

Over the past 18 months, Jonathan Silverstein made no insider transaction in scPharmaceuticals Inc (SCPH). Other recent insider transactions involving scPharmaceuticals Inc (SCPH) include a net purchase of 500,000 shares made by Orbimed Advisors Llc ,

In summary, during the past 3 months, insiders sold 0 shares of scPharmaceuticals Inc (SCPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of scPharmaceuticals Inc (SCPH) were sold and 500,000 shares were bought by its insiders, resulting in a net purchase of 500,000 shares.

scPharmaceuticals Inc (SCPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

scPharmaceuticals Inc Insider Transactions

No Available Data

What does Rhythm Pharmaceuticals Inc do?

Who are the key executives at Rhythm Pharmaceuticals Inc?

Jonathan Silverstein is the director & 10 percent owner of Rhythm Pharmaceuticals Inc. Other key executives at Rhythm Pharmaceuticals Inc include Chief Human Resources Officer Pamela J. Cramer , Chief Technical Officer Joseph Shulman , and Corporate Controller & CAO Christopher Paul German .

Rhythm Pharmaceuticals Inc (RYTM) Insider Trades Summary

Over the past 18 months, Jonathan Silverstein made no insider transaction in Rhythm Pharmaceuticals Inc (RYTM). Other recent insider transactions involving Rhythm Pharmaceuticals Inc (RYTM) include a net sale of 171,662 shares made by Joseph Shulman , a net sale of 85,162 shares made by Pamela J. Cramer , and a net sale of 78,894 shares made by Jennifer Chien .

In summary, during the past 3 months, insiders sold 125,174 shares of Rhythm Pharmaceuticals Inc (RYTM) in total and bought 0 shares, with a net sale of 125,174 shares. During the past 18 months, 592,041 shares of Rhythm Pharmaceuticals Inc (RYTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 592,041 shares.

Rhythm Pharmaceuticals Inc (RYTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rhythm Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sorrento Tech Inc do?

Who are the key executives at Sorrento Tech Inc?

Jonathan Silverstein is the director & 10 percent owner of Sorrento Tech Inc. Other key executives at Sorrento Tech Inc include 10 percent owner Orbimed Capital Gp Iii Llc , 10 percent owner Samuel D Isaly , and 10 percent owner Orbimed Advisors Llc .

Sorrento Tech Inc (ROKA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sorrento Tech Inc (ROKA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sorrento Tech Inc (ROKA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sorrento Tech Inc (ROKA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sorrento Tech Inc Insider Transactions

No Available Data

What does Audentes Therapeutics Inc do?

Who are the key executives at Audentes Therapeutics Inc?

Jonathan Silverstein is the director & 10 percent owner of Audentes Therapeutics Inc. Other key executives at Audentes Therapeutics Inc include President and COO Natalie C. Holles , SVP & Chief Medical Officer Edward R. Conner , and Executive Vice President & CFO Thomas P Soloway .

Audentes Therapeutics Inc (BOLD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Audentes Therapeutics Inc (BOLD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Audentes Therapeutics Inc (BOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Audentes Therapeutics Inc (BOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Audentes Therapeutics Inc Insider Transactions

No Available Data

What does Intercept Pharmaceuticals Inc do?

Who are the key executives at Intercept Pharmaceuticals Inc?

Jonathan Silverstein is the director of Intercept Pharmaceuticals Inc. Other key executives at Intercept Pharmaceuticals Inc include EVP & Chief Financial Officer Andrew Saik , President & R&D and CMO M Michelle Berrey , and Chief Accounting Officer Rocco Venezia .

Intercept Pharmaceuticals Inc (ICPT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Intercept Pharmaceuticals Inc (ICPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intercept Pharmaceuticals Inc (ICPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Intercept Pharmaceuticals Inc (ICPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Intercept Pharmaceuticals Inc Insider Transactions

No Available Data

What does Relypsa Inc do?

Who are the key executives at Relypsa Inc?

Jonathan Silverstein is the director & 10 percent owner of Relypsa Inc. Other key executives at Relypsa Inc include SVP & Chief Commercial Officer J. Scott Garland , SVP & Chief Technology Officer Wilhelm Stahl , and See Remarks Ronald A. Krasnow .

Relypsa Inc (RLYP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Relypsa Inc (RLYP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Relypsa Inc (RLYP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Relypsa Inc (RLYP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Relypsa Inc Insider Transactions

No Available Data

What does NxStage Medical Inc do?

Who are the key executives at NxStage Medical Inc?

Jonathan Silverstein is the director & 10 percent owner of NxStage Medical Inc. Other key executives at NxStage Medical Inc include director & Chief Executive Officer Jeffrey H Burbank , Chief Accounting Officer Kevin Hershberger , and 10 percent owner & other: Possible Member of 10% Group Deerfield Management Company, L.p. (series C) .

NxStage Medical Inc (NXTM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of NxStage Medical Inc (NXTM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NxStage Medical Inc (NXTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

NxStage Medical Inc (NXTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

NxStage Medical Inc Insider Transactions

No Available Data

What does Insulet Corp do?

Who are the key executives at Insulet Corp?

Jonathan Silverstein is the director of Insulet Corp. Other key executives at Insulet Corp include SVP & Chief Technology Officer Mark N Field , VP & CAO and Controller Lauren Budden , and SVP & Global Operations Prem Singh .

Insulet Corp (PODD) Insider Trades Summary

Over the past 18 months, Jonathan Silverstein made no insider transaction in Insulet Corp (PODD). Other recent insider transactions involving Insulet Corp (PODD) include a net sale of 6,401 shares made by Mark N Field , a net sale of 15,300 shares made by Timothy J Scannell , and a net sale of 932 shares made by Luciana Borio .

In summary, during the past 3 months, insiders sold 18,728 shares of Insulet Corp (PODD) in total and bought 100 shares, with a net sale of 18,628 shares. During the past 18 months, 81,763 shares of Insulet Corp (PODD) were sold and 8,951 shares were bought by its insiders, resulting in a net sale of 72,812 shares.

Insulet Corp (PODD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Insulet Corp Insider Transactions

No Available Data

What does Adicet Bio Inc do?

Who are the key executives at Adicet Bio Inc?

Jonathan Silverstein is the director & 10 percent owner of Adicet Bio Inc. Other key executives at Adicet Bio Inc include director & 10 percent owner Orbimed Advisors Llc , director & See Remarks Chen Schor , and Chief Technology Officer Don Healey .

Adicet Bio Inc (ACET) Insider Trades Summary

Over the past 18 months, Jonathan Silverstein made no insider transaction in Adicet Bio Inc (ACET). Other recent insider transactions involving Adicet Bio Inc (ACET) include a net purchase of 4,000,000 shares made by Orbimed Advisors Llc , a net purchase of 4,000,000 shares made by Carl L Gordon , and a net sale of 0 shares made by Chen Schor .

In summary, during the past 3 months, insiders sold 0 shares of Adicet Bio Inc (ACET) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 16,900 shares of Adicet Bio Inc (ACET) were sold and 8,016,000 shares were bought by its insiders, resulting in a net purchase of 7,999,100 shares.

Adicet Bio Inc (ACET)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adicet Bio Inc Insider Transactions

No Available Data

Jonathan Silverstein Mailing Address

Above is the net worth, insider trading, and ownership report for Jonathan Silverstein. You might contact Jonathan Silverstein via mailing address: 601 Lexington Avenue, 54th Floor, New York Ny 10022.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.